Unicycive Therapeutics, Inc. (UNCY)
NASDAQ: UNCY · IEX Real-Time Price · USD
0.400
-0.007 (-1.82%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Company Description
Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States.
Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease.
Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee’s Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.
Unicycive Therapeutics, Inc.
| Country | United States |
| Founded | 2016 |
| IPO Date | Jul 13, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Dr. Shalabh K. Gupta M.D., MPA |
Contact Details
Address: 4300 El Camino Real, Suite 210 Los Altos, California 94022 United States | |
| Phone | 650-384-0642 |
| Website | unicycive.com |
Stock Details
| Ticker Symbol | UNCY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001766140 |
| CUSIP Number | 90466Y103 |
| ISIN Number | US90466Y1038 |
| Employer ID | 81-3638692 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Shalabh K. Gupta M.D., MPA | Founder, Chairman, Chief Executive Officer and President |
| Dr. Pramod Gupta Ph.D. | Executive Vice President of Pharmaceutical and Business Operations |
| Douglas Jermasek M.B.A. | Executive Vice President of Corporate Strategy |
| John W. Townsend CPA | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 18, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jul 16, 2024 | EFFECT | Notice of Effectiveness |
| Jul 16, 2024 | 424B3 | Prospectus |
| Jul 15, 2024 | 8-K | Current Report |
| Jul 15, 2024 | 8-K | Current Report |
| Jul 5, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Jul 2, 2024 | 8-K | Current Report |
| Jun 26, 2024 | 8-K | Current Report |
| Jun 25, 2024 | 8-K | Current Report |
| Jun 20, 2024 | 8-K | Current Report |